acute pancreatitis (AP) is an inflammatory disease characterized by local pancreatic necrosis as well as systemic organ failure. So far, there are only few treatment options for patients with AP. We aimed to investigate the anti-inflammatory abilities of that human bone marrow-derived mesenchymal stem cell (hBM-MSC) in an experimental AP model.

AP was induced in C57BL/6 mice by intraperitoneal administration of cerulein (100µg/kg/h×7dose) at intervals of 1h. 2×105 MSCs were injected in the AP mice through tail vein 6h after the last cerulein injection. Mice were sacrificed at 12h after injection of MSCs, and blood samples and pancreas tissues were obtained.

we first detected the presence of transplanted hBM-MSC in the pancreas of mice with AP, but not the control mice. Our data showed that administration of hBM-MSC to mice with AP lead to: (i) decrease of serum levels of amylase, lipase and myeloperoxidase activities, (ii) downregulation of proinflammatory cytokines such as IL-6 and MIP-2, and (iii) upregulation of anti-inflammatory cytokine, IL10. Moreover, MSC administration resulted in markedly attenuated cerulein-induced histopathological alternations and water contents.

we demonstrate that hBM-MSC attenuates AP signs and indicating that hMB-MSC therapy could be a suitable approach for the treatment of inflammatory disease such as AP.